Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
Monday, 16 September 2013
Medgenics' new team fundamental to firm's continued success, says chairman
Medgenics (LON:MEDG, NYSE:MDGN), which is developing Biopump platform technology, has unveiled a new executive team with a host of industry experience.
It comes as the founder and former president and chief executive Andrew Pearlman retired as of Friday last week (September 13).
He is continuing to serve on the board and as a senior advisor to the company.
Michael Cola, most recently president of Shire's specialty pharma business, becomes president and chief executive.
Dr John Leaman, who brings more than a decade of corporate strategy, finance, venture capital and M&A experience in the life sciences industry, is chief financial officer.
Dr Garry Neil becomes Global Head of Research and Development.
Neil has more than 30 years of clinical development experience in the life sciences industry. Most recently he was a partner atApple Tree Partners, a life sciences private equity fund.
Chairman Sol J Barer said: "Collectively, the new team's relevant experience and knowledge is impressive and will be integral toMedgenics' continued success."
He added: "On behalf of the board and the entire staff at Medgenics, I extend deepest gratitude to Andy Pearlman for his many contributions to our company. Andy has dedicated more than a decade to the development of the Biopump technology, and it is through his efforts and leadership that we have such a strong foundation."